Unlike other niacin compounds, NR does not cause the skin to flush.
ChromaDex (Irvine, CA) gave Nutritional Outlook a preview of what it calls the “next generation vitamin B,” which the company plans to roll out this fall. As Frank Jaksch, ChromaDex founder and CEO explained, nicotanimide riboside(NR), as well as other niacin compounds, is a precursor to nicotinamide adenine dinucleotide (NAD), a crucial cellular co-factor involved in converting ATP. Unlike other niacin compounds, however, NR does not cause the skin to flush because it does not affect the up-regulation of prostaglandins, which causes the flushed effect.
Last July, ChromaDex announced that it had obtained the license to a patent from Cornell University covering a method for synthesizing NR that is cost-effective and commercially viable for large-scale production. (The company said that while NR is linked to multiple health benefits in laboratory models, it is still not available in the market in commercial quantities.) ChromaDex, it seems, is now set for a commercial launch. Ingredient benefits include those for energy metabolism and weight management.
Cracking the code: Advancements in calcium absorption and nutritional understanding
July 23rd 2024Recent research conducted by ILSI U.S. and Canada – a global, nonprofit federation dedicated to advancing precompetitive research in the food, nutrition and health realms – and partially funded by Balchem, has shed light on how to improve predictions of Ca bioavailability across different food matrices.
New study shows that vitamin K2 as MK-7 may have neuroprotective qualities
May 17th 2024Researchers examined the effects of MK-7 and menaquinone-4 (MK-4) on neuroblastoma cells to understand how different forms of vitamin K2 impact the expression of genes involved in neurodegeneration and neuroinflammation.